
Veracyte (VCYT) Stock Forecast & Price Target
Veracyte (VCYT) Analyst Ratings
Bulls say
Veracyte is a leader in the rapidly growing market for next-generation diagnostic tests utilizing comprehensive genomic information to improve cancer diagnosis and treatment decisions. With strong revenue growth, plans to expand overseas, and a promising product pipeline, Veracyte has the potential for sustained long-term revenue growth. Additionally, the company has a strong financial position with no debt and increasing cash flow. However, there are potential risks such as weaker than expected sales, lower margins, and free cash flow.
Bears say
Veracyte is facing significant competition in the genomic diagnostics market, and while their Prosigna and TrueMRD tests show potential, launch delays and slower than expected sales have hindered their growth potential. Additionally, the company's valuation is relatively high compared to industry peers, leaving little room for upside. Furthermore, potential risks such as weaker sales and lower margins pose a threat to the company's financial outlook.
This aggregate rating is based on analysts' research of Veracyte and is not a guaranteed prediction by Public.com or investment advice.
Veracyte (VCYT) Analyst Forecast & Price Prediction
Start investing in Veracyte (VCYT)
Order type
Buy in
Order amount
Est. shares
0 shares